ClinicalTrials.gg
TerminatedNCT04617054Updated Jan 21, 2026

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

A Phase 2 interventional study of AB-106 in Solid Tumor, sponsored by Nuvation Bio Inc.. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Nuvation Bio Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was discontinued early by the Sponsor for business reasons on 06 Dec 2024

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

AB-106 will be administered once a day. Each treatment cycle is defined as 21 days of continuous medication. Dosing will continue until any of the following conditions are met: disease progression, intolerable drug-related adverse events, researchers recommend discontinuation of treatment, withdrawal of informed consent, pregnancy during the study, use of other anti-tumor therapy, loss of follow-up, death and other causes, whichever occurs first.

The study includes a screening period, treatment period, safety follow-up and long-term follow-up.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Nuvation Bio Inc. is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with locally advanced or solid tumors harboring NTRK1, NTRK2, or NTRK3 fusion genes (anticipated to translate into fusion proteins with a functional TrkA/B/C kinase domain);
  2. Participants who had failed standard of care or refused standard of care;
  3. Participants must have had at least 1 as defined by 1.1;
  4. For participants diagnosed with a primary CNS tumor, the following criteria should have been met:

    • Must have received previous treatment, including radiotherapy (with clear progression before C1D1), chemotherapy, and targeted therapy (completed at least 4 weeks before C1D1).
    • At least 1 lesion must be measurable in two dimensions (confirmed by MRI and assessable as per RANO criteria), and each dimension of at least 1 measurable lesion must be ≥1 cm, and can be observed on more than 1 imaging slice.
  5. Male or female participants ≥18 years old;
  6. PS score of ≤1;
  7. The Investigator judged that the participant's was more than 3 months;
  8. Within 7 days prior to enrollment, laboratory tests had to meet the following criteria (requiring no blood or blood product transfusion, no use of hematopoietic stimulants, or other medications to correct blood cells within 14 days prior to enrollment):

    • ≥1.5×109/L, ≥80×109/L, and ≥90 g/L.
    • Serum and serum ALT ≤2.5×the (ULN); AST and ALT ≤5×ULN for participants with liver tumors.
    • Total ≤1.5×ULN. Participants with a known history of Gilbert's syndrome and an abnormal increase in indirect bilirubin are eligible.
    • Serum creatinine ≤2.0×ULN; urine dipstick for urine protein \<2+; if ≥2+, a 24-hour urine protein should be quantified and total urine protein \<1 g.
  9. Coagulation: (INR) ≤1.5, and partial prothrombin time or activated partial thromboplastin time (APTT) ≤1.5×ULN;
  10. Participants must have been able to provide archived or newly obtained tumor tissue specimens (including consent for the collection of new specimens);
  11. During the treatment period and for at least 90 days after completing study drug, participants agreed to use effective measures (excluding males post-vasectomy, or females who were post-sterilization and ). Women of were required to have a negative blood human chorionic gonadotropin (HCG) test within 7 days prior to the first dose;
  12. Prior to enrollment, participants (or their legal representatives) had been fully informed and had signed and dated the form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Underwent treatment in another therapeutic clinical study within 4 weeks prior to the first dose of taletrectinib;
  2. Participants who had suffered a cerebrovascular accident (excluding ) within 3 months before enrollment;
  3. Participants with Grade ≥2 toxicity reactions from previous treatments which did not resolve, except for AEs deemed as not posing a safety risk (such as alopecia, neuropathy, and specific laboratory test abnormalities);
  4. Participants with symptomatic or unstable (participants with asymptomatic brain metastases may be eligible), and those with primary CNS tumors may be included if their condition was stable for at least 7 days;
  5. Participants who underwent major surgery or radiotherapy within 28 days prior to enrollment (participants who received palliative radiotherapy for bone pain and brain metastasis radiotherapy within 2 weeks before enrollment were allowed to participate), or participants who were expected to require major surgery during the study;
  6. Known interstitial lung disease, interstitial fibrosis, or pneumonitis induced by tyrosine kinase inhibitors;
  7. Participants with active, uncontrollable systemic bacterial, viral, or fungal infections, or diseases such as diabetes or hypertension unmanageable with medication, or other systemic diseases that would hinder compliance with the study procedures;
  8. Active or C infection (HBsAg positive and/or HBcAb positive with HBV DNA ≥104 copies or ≥2000 IU/mL; antibody positive and HCV-RNA positive or HCV-RNA>);
  9. History of immunodeficiency, including testing positive for or suffering from other acquired or congenital immunodeficiency diseases, or history of organ transplantation;
  10. Participants who were expected to use systemic strong inhibitors of within 28 days prior to the start of the study drug and/or during the study period, including, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, or strong inducers of CYP3A4, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's Wort, or strong inducers or inhibitors of p-gp;
  11. Participants with a history of other . This did not include those who were cured of non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasm. Participants diagnosed with other malignancies more than 5 years before enrollment could be included only if: (i) there were no active lesions, (ii) the Investigator assessed the risk of recurrence as low, and (iii) the condition would not interfere with the assessment of the efficacy of taletrectinib;
  12. Participants who, in the Investigator's judgment, had other serious acute or chronic physical illnesses, mental illnesses, or laboratory abnormalities, as well as diseases or abnormalities that might pose an excessive risk in relation to participation in the study or administration of the study drug;
  13. Expected to use any other antitumor drugs within 14 days prior to starting the study drug and/or during the study, including traditional Chinese medicines, Chinese patent drugs, and herbal medicines (including decoctions) with clear antitumor indications in the package inserts;
  14. Participants with a known history of neurological or psychiatric disorders, such as epilepsy or dementia, that may affect compliance;
  15. Participants with a history of drug or substance abuse;
  16. Participants with spinal cord compression due to the tumor (unless the participant's pain is fully controlled and neurological function is stable or restored), cancerous meningitis, or ; those assessed by the Investigator to be at risk for brain herniation;
  17. Participants with active peptic ulcers, significant vomiting, chronic diarrhea, intestinal obstruction, malabsorption, or other known diseases that could affect drug absorption; those with swallowing difficulties or other severe conditions that significantly affect drug absorption, such as those who have undergone gastric or intestinal resection;
  18. Participants with a history or current conditions within 3 months prior to enrollment: heart failure ( functional classification ≥3), myocardial infarction, cerebral infarction, unstable angina, arrhythmias requiring treatment, uncontrollable atrial fibrillation (of any grade), coronary or peripheral artery disease, pulmonary embolism, uncontrollable deep vein thrombosis, or other severe thrombosis, or diseases requiring treatment; or whose showed a >470 ms (females) or QTc >450 ms (males) before enrollment.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106

    Drug: AB-106

Interventions

  • DrugAB-106

    600mg QD for each subjects.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Assessed by an Independent Review Committee (IRC) based on the RECIST 1.1 criteria or the RANO criteria.

    Time frame: Approximately 24 months

Secondary outcomes

  1. Objective response rate (ORR)

    Assessed by the Investigator based on RECIST 1.1 or RANO criteria.

    Time frame: Approximately 24 months

  2. Duration of response (DOR)

    Assessed separately by the IRC and the Investigator based on RECIST 1.1 or RANO criteria.

    Time frame: Approximately 24 months

  3. Time to Response (TTR)

    Assessed separately by the IRC and the Investigator based on RECIST 1.1 or RANO criteria

    Time frame: Approximately 24 months

  4. Time to Progress (TTP)

    Assessed separately by the IRC and the Investigator based on RECIST 1.1 or RANO criteria.

    Time frame: Approximately 24 months

  5. Disease control rate (DCR)

    Assessed separately by the IRC and the Investigator based on RECIST 1.1 or RANO criteria.

    Time frame: Approximately 24 months

  6. Intracranial objective response rate (IC-ORR)

    Assessed by the IRC based on the RANO-BM criteria for participants with brain metastases at baseline.

    Time frame: Approximately 24 months

  7. Intracranial duration of response (IC-DOR)

    Assessed by the IRC based on the RANO-BM criteria for participants with brain metastases at baseline.

    Time frame: Approximately 24 months

  8. Intracranial disease control rate (IC-DCR)

    Assessed by the IRC based on the RANO-BM criteria for participants with brain metastases at baseline.

    Time frame: Approximately 24 months

  9. Progression free Survival (PFS)

    Progression free Survival (PFS) as assessed separately by the IRC and the Investigator based on RECIST 1.1 or RANO criteria.

    Time frame: Approximately 30 months

  10. Overall survival (OS)

    Assessed by Kaplan-Meier method.

    Time frame: Approximately 36 months

  11. Safety and tolerability of taletrectinib treatment

    Adverse events (AEs)/Serious adverse events (SAEs)/Adverse events of special interests (AESIs); laboratory tests, vital signs, physical examination, ophthalmological examination, 12-lead electrocardiogram (ECG), etc.

    Time frame: Approximately 36 months

  12. Pharmacokinetics (PK) of taletrectinib

    Plasma concentrations of taletrectinib (in free form)

    Time frame: Cycle 1 Day 1 to Cycle 2 Day 1

07

Study locations

1 site
  • Chinese PLA General Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Dec 2024, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2020
First posted
Nov 5, 2020
StartActual
Jun 1, 2021
Primary completionActual
Dec 6, 2024
CompletionActual
Dec 6, 2024
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04617054
Lead sponsor
Nuvation Bio Inc.
Responsible party
Sponsor
First posted
Nov 5, 2020
Start date
Jun 1, 2021
Primary completion
Dec 6, 2024
Completion
Dec 6, 2024
Last update
Jan 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taletrectinib

Start the discussion